Search Results - subject:"GLP"

Disutility of injectable therapies in obesity and type 2 diabetes mellitus : general population preferences in the UK, Canada, and China

McEwan, Phil; Baker-Knight, James; Ásbjörnsdóttir, Björg - In: The European journal of health economics 24 (2023) 2, pp. 187-196

Persistent link: https://www.econbiz.de/10014327893

Comparative effectiveness and cost-effectiveness of cardioprotective glucose-lowering therapies for type 2 diabetes in Brazil : a Bayesian network model

Cavalcante Nogueira, Ana Claudia; Barreto, Joaquim; … - In: Health economics review 13 (2023) 1, pp. 1-16

can be reduced by three classes of glucose-lowering therapies (GLT), including SGLT2i, GLP-1A, and pioglitazone. However …$. Results In the NMA, SGLT2i [HR: 0.81 (95% CI 0.69-0.96)], GLP-1A [HR: 0.79 (95% CI 0.67-0.94)], and pioglitazone [HR: 0.73 (95 … compared to standard care. SGLT2i and GLP-1A also increased efectiveness, resulting in 0.261 and 0.259 DALYs averted …

Persistent link: https://www.econbiz.de/10014500625